医学
胶质瘤
替莫唑胺
免疫疗法
异柠檬酸脱氢酶
临床试验
肿瘤科
重症监护医学
内科学
生物信息学
免疫系统
癌症研究
免疫学
生物
生物化学
酶
作者
Paulina Śledzińska,Marek Bebyn,Jacek Furtak,Agnieszka Koper,Krzysztof Koper
出处
期刊:Reviews in The Neurosciences
[De Gruyter]
日期:2022-09-05
卷期号:34 (5): 483-516
被引量:11
标识
DOI:10.1515/revneuro-2022-0060
摘要
Abstract Gliomas are the most common primary central nervous system tumors; despite recent advances in diagnosis and treatment, glioma patients generally have a poor prognosis. Hence there is a clear need for improved therapeutic options. In recent years, significant effort has been made to investigate immunotherapy and precision oncology approaches. The review covers well-established strategies such as surgery, temozolomide, PCV, and mTOR inhibitors. Furthermore, it summarizes promising therapies: tumor treating fields, immune therapies, tyrosine kinases inhibitors, IDH(Isocitrate dehydrogenase)-targeted approaches, and others. While there are many promising treatment strategies, none fundamentally changed the management of glioma patients. However, we are still awaiting the outcome of ongoing trials, which have the potential to revolutionize the treatment of glioma.
科研通智能强力驱动
Strongly Powered by AbleSci AI